CLIENT RESULT
Diagnostics

Before the precision medicine strategy, the precision medicine map.

Andrew Aijian, PhD

Partner
View Profile
capabilities
Market Opportunity Landscaping
Project Details
capability
Market Opportunity Landscaping

Objective

A leading global biopharma extending its precision medicine strategy beyond oncology needed a comparable fact base across four markets and four disease areas. Andrew's team produced the cross-market diagnostic readiness map the leadership team needed before downstream decisions could be made with confidence.
Key Metrics
96
Stakeholder Interviews
320
Quantitative Surveys
4
Markets Profiled

Our Approach

Andrew Aijian anchored the work with his depth across oncology ipa’abiomarkers, European Dx policy, and global diagnostic market intelligence. The engagement was designed around a single structural commitment: every market would be assessed against the same set of dimensions in the same way, so that the resulting fact base would be comparable across the matrix rather than four standalone country studies.

Four disease areas were evaluated (solid tumor oncology, hematological oncology, cardiology, neurology), each with a five-dimension assessment: regulatory pathway, reimbursement architecture, diagnostic technology adoption, laboratory infrastructure, and three-year forward trends per market. Populating the matrix required research at scale: 96 stakeholder interviews and 320 quantitative surveys, balanced across academic and community settings and across clinical and laboratory roles, with an in-country research lead in each market to ground the work in local dynamics rather than translated assumptions. Secondary research ran in parallel across regulatory agency policies, payor coverage decisions, lab accreditation databases, and clinical guidelines, anchored by the firm's proprietary DxBooks diagnostics market intelligence database for technology and vendor share work.

During synthesis, cross-market patterns surfaced, including the global dominance of a small set of Dx manufacturers in established modalities, the consistent push toward IVDs as LDT regulation tightened across geographies. Market-specific divergences were also evaluated, such as the role of commercial reference labs in Japan, the centrality of Tier 3 hospitals in China, the IVDR transition dynamics in Germany, the FDA LDT rule reshaping the U.S. landscape. Disease-area patterns surfaced as a third axis: the relative maturity of precision diagnostics in oncology against the early-stage adoption in cardiology and neurology, where biochemical testing still anchors the patient journey. The output was a single comparable view across the matrix, with implications for diagnostic partnership strategy, market access investment, and regulatory engagement drawn at both the cross-market and market-specific level.

Outcome

The leadership team came out of the engagement with a comparable fact base across four markets, four disease areas, and the full diagnostic stack that supports them. Where downstream decisions had previously rested on regional memory and oncology-anchored intuition, the team now had a comprehensive view across markets. The database served as a concrete inventory of where pre-competitive infrastructure investment, advocacy, and partnership work would need to happen before precision therapies arrived.

With the map in place, the leadership team was positioned to take the foundational fact base into the downstream decisions it was built to support: CDx partnership architecture, market access strategy, regulatory engagement, and the pre-competitive infrastructure investments that would have to precede the next phase of precision medicine's expansion.

Project Details
Geographic Scope
U.S., Germany, Japan, China
Precision Medicine is evolving at a rapid pace

Discover how we can help

Get in Touch